Cumberland Pharmaceuticals Achieves 31% Revenue Growth in Q4 2025 with Strategic Advances Cumberland Pharmaceuticals reports a remarkable 31% increase in fourth quarter 2025 revenue. The company continues to innovate and expand its presence in key international markets.

Cumberland Pharmaceuticals Achieves 31% Revenue Growth in Q4 2025 with Strategic Advances #United_States #Nashville #Cumberland_Pharmaceuticals #Vibativ #Talicia

Cumberland Pharmaceuticals Partners with Premier, Inc. for Vibativ® Distribution to Healthcare Facilities Cumberland Pharmaceuticals recently announced that its antibiotic, Vibativ®, has been added to a group purchasing agreement with Premier, Inc., enhancing access across numerous healthcare facilities.

Cumberland Pharmaceuticals Partners with Premier, Inc. for Vibativ® Distribution to Healthcare Facilities #United_States #Nashville #Cumberland_Pharmaceuticals #Premier_Inc. #Vibativ

Tabuk Launches Vibativ®: A Game-Changer in Antibiotics for Saudi Patients Tabuk Pharmaceutical Manufacturing announces the launch of Vibativ®, an FDA-approved antibiotic, to combat serious infections in Saudi Arabia. This innovative treatment offers hope against drug-resistant bacteria.

Tabuk Launches Vibativ®: A Game-Changer in Antibiotics for Saudi Patients #Saudi_Arabia #Riyadh #Tabuk #Vibativ #Antibiotic

Cumberland Pharmaceuticals Achieves Remarkable 23% Revenue Surge in First Half of 2025 Cumberland Pharmaceuticals Inc. reports a stunning 23% revenue growth year-to-date, driven by FDA-approved product sales, showcasing their strong market presence.

Cumberland Pharmaceuticals Achieves Remarkable 23% Revenue Surge in First Half of 2025 #United_States #Nashville #Cumberland_Pharmaceuticals #Vibativ #Caldolor

Cumberland Pharmaceuticals Expands Vibativ Access via Vizient Contract for Healthcare Providers Cumberland Pharmaceuticals has secured a new contract with Vizient to provide the Vibativ® 4-Vial Starter Pak. This enhances accessibility for healthcare providers across the nation.

Cumberland Pharmaceuticals Expands Vibativ Access via Vizient Contract for Healthcare Providers #United_States #Nashville #Cumberland_Pharmaceuticals #Vibativ #Rx_medications

Cumberland Pharmaceuticals Announces Annual Financial Results for 2024, Insights into Upcoming Plans Cumberland Pharmaceuticals Inc. is set to release its annual financial results for 2024 on March 4, 2025, highlighting its commitment to patient care and ongoing clinical programs.

Cumberland Pharmaceuticals Announces Annual Financial Results for 2024, Insights into Upcoming Plans #USA #Nashville #Cumberland_Pharmaceuticals #Acetadote #Vibativ

Cumberland Pharmaceuticals’ Vibativ® Now Approved in China: A Milestone for Antibiotic Availability Cumberland Pharmaceuticals and SciClone Pharmaceuticals celebrate the approval of Vibativ® in China, enhancing access to life-saving antibiotics for pneumonia and serious skin infections.

Cumberland Pharmaceuticals’ Vibativ® Now Approved in China: A Milestone for Antibiotic Availability #China #Shanghai #Cumberland #Vibativ #SciClone